Teva Pharmaceutical Industries Ltd. announced the departure of its chief executive officer after just three years and said it would undertake a thorough review of its business, leaving the world’s largest generic-drug maker without a permanent leader following lowered profit forecasts that sent the share price plunging. CEO Erez Vigodman has stepped down, and Chairman Yitzhak Peterburg will hold the job on an interim basis while a search is conducted for a successor, the Petach Tikva, Israel-based company said in a statement late Monday.